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Abstract
The widespread presence of plasmid-mediated quinolone resistance determinants, particularly qnr genes, has become a
current issue. By protecting DNA-gyrase from quinolones, Qnr proteins confer a low level quinolone resistance that is not
sufficient to explain their emergence. Since Qnr proteins were hypothesized to act as DNA-binding protein regulators, qnr
genes could have emerged by providing a selective advantage other than antibiotic resistance. We investigated host fitness
of Escherichia coli isogenic strains after acquisition of the qnrA3 gene, inserted either alone onto a small plasmid (pBR322), or
harbored on a large conjugative native plasmid, pHe96(qnrA3) found in a clinical isolate. The isogenic strains were derived
from the susceptible E. coli CFT073, a virulent B2 group strain known to infect bladder and kidneys in a mouse model of
pyelonephritis. In vitro experiments included growth analysis by automatic spectrophotometry and flow cytometry, and
competitions with CFU enumeration. In vivo experiments included infection with each strain and pairwise competitions in
absence of antimicrobial exposure. As controls for our experiments we used mutations known to reduce fitness (rpsL K42N
mutation) or to enhance fitness (tetA deletion in pBR322). E. coli CFT073 transformed with pBRAM(PBR322-qnrA3) had
significantly higher maximal OD than E. coli CFT073 transformed with pBR322 or pBR322DtetA, and in vivo competitions
were more often won by the qnrA3 carrying strain (24 victories vs. 9 loss among 42 competitions, p=0.001). In contrast,
when pHe96(qnrA3) was introduced by conjugation in E. coli CFT073, it exerted a fitness cost shown by an impaired growth
observed in vitro and in vivo and a majority of lost competitions (33/35, p,0.0001). In conclusion, qnrA3 acquisition
enhanced bacterial fitness, which may explain qnr emergence and suggests a regulation role of qnr. However, fitness was
reduced when qnrA3 was inserted onto multidrug-resistant plasmids and this can slow down its dissemination without
antibiotic exposure.
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Introduction
Fluoroquinolones are antibacterial drugs that bind to type II
topoisomerases (DNA gyrase and topoisomerase IV) and inhibit
DNA re-ligation after enzyme cut [1,2]. These drugs are very
useful, especially for treatment of urinary tract infections due to
Enterobacteriaceae [1]. Fluoroquinolone resistance rate has increased
much for the last years and is mostly due to their large use [3,4].
Classical mechanisms of resistance are chromosomal mutations in
the genes encoding the quinolone targets or causing enhanced
efflux [1,5]. More recently, plasmid-mediated resistance determi-
nants have been reported encoding for different proteins: the Qnr
proteins which belong to the pentapeptide repeat family (PRP)
[6,7], the acetyltransferase AAC(69)-Ib-cr [8] and the QepA active
efflux pump [9]. Enterobacteriaceae with plasmid-mediated quinolone
resistance (PMQR) due to qnr genes have been worldwide
described with an increase in their prevalence [10]. This rapid
widespread is surprising because the acquisition of a qnr gene only
confers a low-level resistance to fluoroquinolones [6,11,12].
Although this low-level resistance can be clinically relevant and
probably contributed to qnr dissemination [13,14], this does not
fully explain the emergence of the qnr genes.
In clinical strains, qnr genes were essentially found on multi-drug
resistance (MDR) plasmids, but chromosomal qnr genes have been
also described in environmental bacterial species that are the
supposed reservoir of these genes [15–18]. The native function of
Qnr proteins still remains unknown [10]. They bind to type II
topoisomerases and thus protect them from quinolone binding and
action [7,19,20]. Functional and crystallography analyses of PRPs
closed to Qnr are in favor of a role of Qnr proteins in
topoisomerase regulation [21–25].
Most antibiotic resistance mechanisms, particularly fluoroquin-
olone resistance mutations, are associated with a fitness cost [26–
29]. However, fitness cost of horizontal transferable resistance
genes is often compensated by the regulation of transcription
factors encoded by other genes harbored onto the same plasmid
[30]. Nonetheless, interplay between resistance and fitness are not
always concordant, and bacteria can reverse the cost induced by
resistance acquisition. Several mutations could provide both
enhanced fitness and increased resistance [29,31]. Emergence of
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fitness, and not only by the antibiotic use [26]. We hypothesized
that Qnr proteins have an effect on bacterial growth and fitness,
which may have contributed to the emergence of qnr genes in
commensal bacteria.
The aim of our study was to evaluate the impact of the qnr gene
acquisition on bacterial fitness. Therefore we compared the fitness
of isogenic strains of Escherichia coli with and without the qnrA3
gene, whether alone onto a small plasmid or carried onto a large
conjugative multi-drug-resistant native plasmid. Growth and
competitive performances were studied in vitro and in vivo using a
mouse model of pyelonephritis.
Results
Description of the isogenic systems expressing qnr or not
Two systems of isogenic strains were derived from E. coli
CFT073, a virulent strain belonging to the phylogenetic group B2
and whose genome has been sequenced [32]. This strain was
originally used to set the murine model of pyelonephritis used in
this study [33]. We selected a streptomycin resistant mutant (Sm
R)
of E. coli CFT073 in order to have a resistance marker for the
recipient strain after acquisition of the plasmid pHe96, which is a
multidrug resistant plasmid not mediating streptomycin resistance.
This mutant was selected using 160 mg/ml streptomycin at a
proportion of ca.10
29 and harbored a rpsL K42N mutation which
is consistent with its high level of resistance (MIC.512 mg/ml)
and the stability of this resistance. Although pHe96 contains an
ant30-I gene known to confer streptomycin resistance [34], this
gene is truncated and we confirmed that pHe96 does not confer
streptomycin resistance by transferring pHe96 into E. coli J53. The
MIC of streptomycin was 4 mg/l for this transconjugant and was
stable.
The first isogenic system included five strains: E. coli CFT073, E.
coli CFT073 (pBR322) and E. coli CFT073 transformed with three
other plasmids derived from pBR322 and described in Figure S1:
pBRDtetA where the tetracycline resistance gene (tetA) was deleted,
pBRAM1 where the qnrA3 gene was cloned including the 24-bp
DNA motif upstream from qnrA3, and pBRAM2 where qnrA3 was
cloned including the 233-bp DNA motif upstream. In both
pBRAM1 and pBRAM2, qnrA3 was inserted into pBR322 by
inactivating the tetA gene. Minimal inhibitory concentrations
(MIC) of quinolones performed on the five strains showed that
qnrA3 expressed quinolone resistance equally (Table 1) with an
increase of 4-, 8-, 10- and 16-fold for nalidixic acid, ofloxacin,
ciprofloxacin and norfloxacin, respectively.
The second isogenic system included three strains: E. coli
CFT073-Sm
R, E. coli CFT073-Sm
R(pHe96), and a variant of
this transconjugant named E. coli CFT073-Sm
R(pHe96) ‘‘R42’’,
obtained after one passage in the mouse and which showed
improved growth in vitro and in vivo and higher plasmid stability
(see below). The evolved variant ‘‘R42’’ had the same
phenotype for antibiotic resistance than the original strain
CFT073-Sm
R(pHe96) including for streptomycin resistance.
The acquisition of pHe96 conferred, as described previously
[16], a 62- and 50-fold increase in the MIC of ciprofloxacin
and norfloxacin (Table 1), respectively, because this plasmid
harbored the aac69-Ib-cr gene in addition to qnrA3 [16]. In
contrast, ofloxacin and nalidixic acid MICs were the same for
the transconjugants CFT073-Sm
R(pHe96) and for E. coli
CFT073(pBRAM1) and E. coli CFT073(pBRAM2) confirming
that aac69-Ib-cr has no effect on these quinolones, and showing
that the expression of qnrA3 was similar whether it was
harbored on the small plasmid derived from pBR322 or on
the large clinical plasmid from which qnrA3 originated [11,16].
The ‘‘R42’’ variant showed similar sensitivity to quinolones as
it parental strain.
Clinical E. coli isolates carrying a conjugative multidrug resistant
plasmid harboring a qnr gene were also tested in the in vitro
experiments along with the strain E. coli J53, a K-12 derivative
used as a recipient strain for conjugation [35,36]. Description of
the strains, their qnr allele and the quinolone resistance conferred
(increase in quinolone MICs observed for the transconjugants) was
done previously [11,13,35,37]. E. coli J53 transconjugants
harboring qnr-positive plasmids were studied in similar in vitro
experiments as were the two isogenic systems based on E. coli
CFT073 (Table S1).
E. coli CFT073-Sm
R was used as a negative control for host
fitness since it has been shown that streptomycin resistance, and
especially the rpsL mutation K42N, had a fitness cost [26,38,39].
E. coli CFT073(pBRDtetA) was used as a positive control with
regard to E. coli CFT073(pBR322) since the tetA gene has been
shown to have a cost for growth when carried by pBR322 and
constitutively expressed [40,41].
In vitro growth capacity of strains harboring qnrA3
In vitro growth capacity was measured by automated
spectrophotometry for the calculation of the maximal growth
rate, the doubling time and the maximal optical density, and by
flow cytometry for the size of bacterial cells.
Growth parameters of E. coli CFT073 and its four isogenic
strains harboring the plasmid pBR322 or one of its derivates
(pBRDtetA, pBRAM1 and pBRAM2) are shown in Table 2.
Maximal OD was significantly higher for all strains harboring a
qnrA3 carrying plasmid. This gain was not due to the inactivation
of tetA, since the increase in maximal OD was significantly higher
for E. coli CFT073 transconjugants harboring pBRAM1 or
pBRAM2 (acquisition of qnrA3 at the place of tetA) than for the
transconjugant harboring pBRDtetA. No significant difference was
seen in the doubling time between strains where qnrA3 was present
(E. coli CFT073 transformed with pBRAM1 or pBRAM2) and
those where qnrA3 was absent (E. coli CFT073 transformed with
pBRDtetA or pBR322).
Acquisition of the plasmid pHe96 by E. coli CFT073-Sm
R was
responsible for a significant lengthening of doubling time and
Table 1. Minimal Inhibitory Concentrations (MIC) of
quinolones against the strains of the two isogenic systems
derived from E. coli CFT073.
E. coli strains MIC
a (mg/ml)
NAL NOR OFX CIP AMK TOB
E. coli CFT073 2 0.064 0.094 0.012 1.5 0.75
E. coli CFT073(pBR322) 2 0.064 0.094 0.012 1.5 0.5
E. coli CFT073(pBRDtetA) 2 0.064 0.094 0.012 1.5 0.5
E. coli CFT073(pBRAM1) 8 1 0.75 0.125 1 0.5
E. coli CFT073(pBRAM2) 8 1 0.75 0.125 1.5 0.5
E. coli CFT073-Sm
R 2 0.064 0.094 0.012 1.5 0.75
E. coli CFT073-Sm
R(pHe96) 6 3 0.75 0.75 48 32
E. coli CFT073-Sm
R(pHe96) ‘‘R42’’ 6 3 0.75 0.75 48 32
aMinimal inhibitory concentrations measured by E-test for quinolones and
aminoglycosides. NAL, nalidixic acid; NOR, norfloxacin; OFX, ofloxacin; CIP,
ciprofloxacin; AMK, amikacin; TOB, tobramycin.
doi:10.1371/journal.pone.0024552.t001
Enhanced Fitness Due to qnr
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shown above for pBRAM plasmids. Similar results were
obtained in brain heart infusion and minimal media (data not
shown). The ‘‘R42’’ variant of E. coli CFT073-Sm
R(pHe96)
showed significantly better growth parameters than the original
transconjugant strain but stayed below the control strain E. coli
CFT073-Sm
R. Comparing results between E. coli CFT073-Sm
R
with its parental strain E. coli CFT073 confirmed that the
streptomycin resistance due to the rpsL K42N mutation [38] was
associated with a decrease in maximal growth rate (0.95 logOD/
h+/20.02 for E. coli CT073 vs. 0.7 logOD/h+/20.01 for E. coli
CFT073-Sm
R) and increase in the doubling time (18.9 h+/
20.74 for E. coli CFT073 vs. 25.9 h+/20.5 for E. coli CFT073-
Sm
R). Overall, the decrease in growth capacity conferred by the
acquisition of pHe96 seemed to reduce fitness less than the rpsL
mutation did.
Results (arbitrary unit with 95% CI) of flow cytometry are
presented in the Figure 1. Sizes measured by flow cytometry were
20.6 [18.1–23.1], 19.1 [18–20.2] 19.9 [19–20.8], 20.6 [20–21.2]
for the E. coli CFT073 wild type strain and its transformants with
pBR322 (tet+, qnr2), with pBRAM1 (tet2, qnr+), and with
pBRAM2 (tet2, qnr+), respectively. For E. coli CFT073-Sm
R, its
transconjugant with pHe96 and the variant isolate R42 of this
transconjugant, sizes were 32.8 [30.8–34.8], 28.9 [26.8–31], and
30.1 [27.9–32.3], respectively, which were all 34.5% higher than
those of E. coli CFT073. This showed that the acquisition of qnrA3
onto pBRAM1 or pBRAM2 or onto pHe96 did not change
significantly the size of bacteria, contrarily to the mutation of the
recipient strain E. coli CFT073-Sm
R, which was responsible for the
increase in bacterial cell size.
Enhanced fitness after acquisition of qnrA3 onto pBR322
derived plasmids
In vitro competitive assays were run six times by cultivating E. coli
CFT073(pBRAM1) (qnrA3+)o rE. coli CFT073(pBRAM2) (qnrA3+)
with E. coli CFT073(pBR322) (tetA+)o rE. coli CFT073 in a 1:1
ratio. Population increase was measured by CFU counting.
Relative Fitness was calculated as the ratio of the increase of each
population (see material and methods for details) [42–45].
Comparing with E. coli CFT073(pBR322), estimated Relative
Fitness (RF) was close to 1 (1.03+/20.19), meaning that none of
the two competing strains had a selective advantage upon the
other in vitro. Comparing with E. coli CFT073, RF was estimated at
1.12+/20.2, showing that the entire plasmid had no significant
biological cost. The mean plasmid loss was less than 3% after 30
generations for all the strains harboring pBR322-derivatives.
We performed in vivo experiments with the strain E. coli
CFT073(pBRAM2) rather than with E. coli CFT073(pBRAM1) in
order to be closer to clinical conditions (233-bp vs. 24-bp upstream
sequence). In competitive infections (Figure 2A), E. coli
CFT073(pBRAM2) (qnrA3+) had a significant advantage upon E.
coli CFT073(pBR322) (tetA+) with 22 organs/25 where it had
takeover versus only 2/25 where it had lost competition
(p,0.0001). This selective advantage was confirmed when
competitions were run against E. coli CFT073(pBRDtetA)( qnr2)
(Figure 2B). Indeed among 37 competitions, 24 were won by the
qnrA3-positive strain, 4 were judged as tie because the ratio of the
two populations was 1 (+/20.2) and 9 were lost (p=0.01). At day
10, a median competitive index was calculated for qnr-positive
strains as described previously [29]. It was 1.27+/20.16 in
bladders and 13.9+/27.2 in kidneys.
Table 2. In vitro growth parameters for the strains of the first isogenic system based on E. coli CFT073 carrying pBR322 derivatives
harboring qnrA3 or not.
E. coli strains Maximal growth rate in log(OD)/h. Doubling time in min Maximal OD
mean p
a mean p
a mean p
a
CFT073(pBRDtetA)0 . 9 6 ( +/20.02) - 18.9 (+/20.3) - 1.07 (+/20.02) -
CFT073(pBR322) 0.94 (+/20.02) 0.21 19.2(+/20.3) 0.21 1.05 (+/20.06) 0.6
CFT073(pBRAM1) 0.94 (+/20.01) 0.17 19.2 (+/20.3) 0.17 1.11 (+/20.02) 0.005
CFT073(pBRAM2) 0.94 (+/20.02) 0.13 19.2 (+/20.5) 0.13 1.10 (+/20.02) 0.01
Data obtained from automatic OD measurements (n=15) in Trypticase Soy Broth and expressed as mean and confidence interval 95%.
aThe comparison was performed with a Wilcoxon test between each strains and the corresponding control qnr-negative strain CFT073(pBRDtetA). p,0.05 was
considered significant.
doi:10.1371/journal.pone.0024552.t002
Table 3. In vitro growth parameters for the strains of the second isogenic system based on acquisition of the multidrug resistant
qnrA3-positive plasmid pHe96.
E. coli strains Maximal growth rate in log(OD)/h. Doubling time in min Maximal OD
mean p
a mean mean p
a mean
CFT073-Sm
R 0.70 (+/20.01) - 25.9 (+/20.5) - 1.08 (+/20.01) -
CFT073-Sm
R(pHe96) 0.67 (+/20.02) 0.02 27.1 (+/20.9) 0.02 0.94 (+/20.03) ,0.0001
CFT073-Sm
R(pHe96) R42 0.70 (+/20.01) 0.8 26.1 (+/20.8) 0.8
b 0.97 (+/20.02) ,0.0001
aThe comparison was performed with a Wilcoxon test between each strains and the corresponding control qnr-negative strain CFT073-Sm
R. p,0.05 was considered
significant.
bThe difference between the ‘‘R42’’ variant and E. coli CFT073-Sm
R (pHe96) was significant (p=0.04).
doi:10.1371/journal.pone.0024552.t003
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vivo experiments
In vitro, no plasmid loss was observed after daily culture of
E. coli CFT073(pBR322), E. coli CFT073(pBRAM2) and E. coli
CFT073(pBRDtetA). In vivo, the mean loss of the plasmids pBR322
and pBRAM2 in single strain infections (data not shown) was 47%
and 67%, respectively, which was not statistically different. In the
competitive experiments, the global plasmid loss was higher when
we used E. coli CFT073(pBR322) as a control (37% at day 5 and
80% at day 10) than when we used E. coli CFT073(pBRDtetA) (3%
at day 5 and 11% at day 10). This suggests that the high plasmid
loss observed in the competition with tetA-bearing cells corre-
sponded mainly to the loss of pBR322.
In the competitive assays where E. coli CFT073(pBRDtetA) was
used for control, among 45 organs studied, 4 (9%) organs showed
only ampicillin-susceptible colonies corresponding to a plasmid
loss of 100%. When E. coli CFT073(pBR322) was used as control,
it was 10/35 (29%) organs showing only ampicillin-susceptible
colonies. Although we excluded these organs in the final counting,
it showed that pBR322-derived plasmids were more stable in vivo
when they carried a qnrA3 gene that when they did not (p=0.038),
even considering the biological cost of tetA.
Fitness cost due to acquisition of conjugative multidrug
resistance plasmids harboring qnr
Reduced growth capacity of E. coli after pHe96 acquisition
suggested a fitness cost. This was confirmed by the results of the in
vitro competitive assays (eight repeated experiments growing
together E. coli CFT073-Sm
R and E. coli CFT073-Sm
R(pHe96))
where relative fitness index (RF) of E. coli CFT073-Sm
R(pHe96)
was significantly less than 1 (0.67+/20.17). The relative fitness of
the ‘‘R42’’ variant was similar with an index of 0.68+/20.14.
Plasmid loss measured for E. coli CFT073-Sm
R(pHe96) was 65%
after 30 generations. In contrast, plasmid loss was only 3% for its
variant isolate R42 suggesting a compensatory mutation in the
chromosome or the plasmid. To investigate whether the reduced
growth observed with pHe96 exists for other qnr genes and other
qnr-positive MDR plasmids, we studied the in vitro growth capacity
of E. coli J53 and of its transconjugants carrying five different qnr-
positive and MDR plasmids previously described [13,35,37]:
pHm13 (qnrA1), pHm477 (qnrA1), pHe96 (qnrA3), pPS105 (qnrS1),
and pU1696 (qnrB4). No difference was seen between growth
parameters of the strain E. coli J53 and those of the five qnr-positive
transconjugants (Table S1).
When mice were inoculated by the strain E. coli CFT073-Sm
R
(pHe96), the bacterial density in bladders and kidneys was
significantly lower than with the control strain, either at day 2,
day 5 or day 10 (Figure 3). In addition, the number of mice where
the strain failed to induce a persistent UTI was higher with the
transconjugant than with the parental strain: 3 versus 0 for
bladders and 7 versus 2 for kidneys (p=0.003). The results were
similar for the ‘‘R42’’ variant carrying the plasmid pHe96 but less
than with the original transconjugant. This suggests that a
compensatory mutation might have occurred in this variant when
it was cultivated into the mouse for the first passage. In competitive
experiments, E. coli CFT073-Sm
R(pHe96) lost the competition in
33 out of 35 organs (p,0.05) with regard to the control strain E.
coli CFT073-Sm
R confirming the fitness cost of pHe96 acquisition
(Figure 4A). A similar rate of lost experiments was found for the
‘‘R42’’ variant (Figure 4B). The mean loss of pHe96 was less than
20% for the strains E. coli CFT073-Sm
R(pHe96) and its variant
‘‘R42’’, which was expected since these plasmids were coming
from clinical isolates. The median value of the competitive index
for the transconjugants carrying pHe96 was 0.0012+/20.001. No
competition has been run opposing the two pHe96 transconju-
gants because it was not possible to distinguish them.
We also tested, in competitive experiments against the E. coli
CFT073strainand using the same UTImouse model,twoqnr-positive
Figure 1. Cell size measured by flow cytometry for the strains of the two isogenic systems. Each graphic compares size measurement for
bacterial cell populations consisting of the reference susceptible strain E. coli CFT073 (in black) and of the tested strain : E. coli CFT073(pBR322) (qnr-
negative) in red (part A), E. coli CFT073(pBRAM1) (qnrA3-positive) in yellow (part B), E. coli CFT073(pBRAM2) (qnrA3-positive) in pink (part C), E. coli
CFT073-Sm
R (qnr-negative) in blue (part D), E. coli CFT073-Sm
R(pHe96) (qnrA3-positive) in green (part E) and its variant R42 in purple (part F).
Measurements were made separately, not in a competitive assay.
doi:10.1371/journal.pone.0024552.g001
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(qnrS1) (Figure S2). In these non-isogenic competitions, the susceptible
strain E. coli CFT073 won 53 of 57 competitions (kidneys and
bladders)uponE.coli Hm13 (qnrA1)and 40 of 65competitionsupon E.
coli PS105 (qnrS1)( p ,0.001). This confirmed that the fitness cost
attributed to the acquisition of pHe96 was not specific to this plasmid
but was similarly observed with other qnr-positive MDR plasmids.
Discussion
The interplay between resistance and fitness is a challenging
issue when increase of antibiotic resistance is observed worldwide
[26]. Selection pressure due to the increase in antibiotic
prescription explains the increase in resistance in most of the
settings [3] and quinolone resistance was so far associated to a
fitness cost when it was due to mutations either in the
topoisomerase genes or in the efflux operons [27–29,45–49].
The emergence of plasmid-mediated resistance determinants
questioned about links between acquisition of resistance and
selective advantage. Although plasmid acquisition brings a fitness
cost, the stability of native plasmids varied according to the host
and the presence of drug addiction systems may compensate this
plasmid cost [50,51]. For some antibiotic resistance determinants
described recently, such as CTX-M beta-lactamases [52,53], we
Figure 2. Enhanced fitness observed in competitive infections for E. coli CFT073 after qnrA3 acquisition onto pBR322. Each symbol
represents the bacterial ratio (number of CFU for the qnr-positive strain/number of CFU for the qnr-negative isogenic strain) measured in organs (blue
diamond=kidneys, red circle=bladder) collected five and ten days after inoculation of a 1:1 mix of the two strains. When the ratio was equal to 1+/
20.2, it was considered as tie. Part A: competitions experiments opposing E. coli CFT073(pBR322) (qnr2, tetA+) and E. coli CFT073(pBRAM2) (qnrA3+,
tetA2). Fifteen mice were inoculated, 15 bladders and 10 pairs of kidneys were efficiently infected. Competition was won 22 times by E. coli
CFT073(pBRAM2) (qnrA3+, tetA2), was lost 2 times, and one was tie (p,0.0001). Part B: competitions opposing E. coli CFT073(pBRDtetA)( qnr2, tet2)
and E. coli CFT073(pBRAM2) (qnrA3+, tet2). Twenty-three mice were inoculated, 20 bladders and 17 pairs of kidneys were efficiently infected.
Competition was won 24 times by E. coli CFT073(pBRAM2) (qnrA3+, tetA2), was lost 9 times, and 6 was tie (p,0.0001).
doi:10.1371/journal.pone.0024552.g002
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resistance plasmid pHe96 (qnrA3). Part A: Bacterial density (log10CFU/g of tissue) in bladders collected two, five and ten days after inoculation by
E. coli CFT073-Sm
R (qnr2, purple plot), E. coli CFT073-Sm
R(pHe96) (qnrA3+, light green plot) and E. coli CFT073-Sm
R(pHe96) R42 variant (qnrA3+, dark
green plot). At day 2, bacterial density was 6.79+/20.35, 4.95+/20.8 (p,0.0001), and 4.9+/20.65 (p,0.0001), respectively; at day 5, it was 4.61+/
20.25, 3.24+/20.3 (p,0.0001) and 3.79+/20.5 (p=0.03), respectively; and at day 10, 5.47+/20.8, 2.91+/20.6 (p=0.0004) and 2.85+/20.5 (p=0.001),
respectively. At least 10 mice were studied per group. Part B : Bacterial density (log10CFU/g of tissue) in kidneys collected two, five and ten days after
inoculation by E. coli CFT073-Sm
R (qnr2, purple plot), E. coli CFT073-Sm
R(pHe96) (qnrA3+, light green plot) and E. coli CFT073-Sm
R(pHe96) R42 variant
(qnrA3+, dark green plot). Results were respectively 4.29+/20.53, 3.14+/20.64 (p=0.005) and 3.53+/20.46 (p=0.053) at day 2; 4.29+/20.61, 2.94+/
20.6 (p=0.02), and 4.23+/20.43 (p=0.06) at day 5; and 4.81+/20.6, 3.26+/0.63 (p=0.012 and 3.3+/21.59 (p=0.04) at day 10. At least 10 mice were
studied per group.
doi:10.1371/journal.pone.0024552.g003
Enhanced Fitness Due to qnr
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24552know that they have been transferred from environmental
bacteria harboring the resistance genes as chromosomal-borne,
to human commensal bacteria, mainly E. coli, through mobile
elements such as plasmids [54]. For quinolone resistance, such
transfer may have occurred since similar qnr genes are
chromosome-borne in environmental bacteria [18]. However,
the persistence of qnr genes on plasmids is not fully explained by
the quinolone selective pressure since there are numerous other
effective mechanisms to obtain quinolone resistance such as
stepwise chromosomal mutations in the target genes [55] and in
the several efflux systems present in E. coli [56]. We hypothesized
that qnr genes confer a selective advantage outside the quinolone
exposure.
To study the impact on fitness of qnr acquisition, we compared
in vitro growth curves, in vitro pairwise competition, and in vivo single
culture and pairwise competition, which are usual methods found
in literature [26,28,29,42–45,57]. Pairwise competitions are
usually more sensitive than single cultures to reveal a fitness
change, and in vivo assays are more relevant than in vitro assays
since the complex growth environment is closer to reality [26].
This justifies the conclusions we drew on qnr impact on fitness,
which were based on the results of in vivo competitions assays. We
chose the mouse model of pyelonephritis for in vivo experiments
because it was well validated and recently used for studying the
interplay in fluoroquinolone resistance mutations and bacterial
fitness [29]. Marcusson and colleagues showed that although the
Figure 4. Reduced fitness observed after pHe96 acquisition in competitive infections in absence of antimicrobial exposure. Each
symbol represents the ratio (number of CFU for the qnr-positive strain/number of CFU for the qnr-negative isogenic strain) in organs (blue
diamond=kidneys, red circle=bladder), collected five and ten days after inoculation of a 1:1 mix of the two strains. Part A: competition experiments
opposing E. coli CFT073-Sm
R (qnr2) and E. coli CFT073-Sm
R(pHe96) (qnrA3+). Twenty mice were inoculated, 19 bladders and 16 pairs of kidneys were
efficiently infected. Competition was lost 33 times by E. coli CFT073-Sm
R(pHe96) (qnrA3+), and won only 2 times (p,0.0001). Part B: competition
experiments opposing E. coli CFT073-Sm
R (qnr2) and E. coli CFT073-Sm
R(pHe96) variant ‘‘R42’’ (qnrA3+). The R42 variant was selected from kidneys
that were infected by E. coli CFT073-Sm
R(pHe96). Twenty mice were inoculated, 18 bladders and 16 pairs of kidneys were efficiently infected.
Competition was lost 33 times by the qnrA3-positive strain with only one won (p,0.0001).
doi:10.1371/journal.pone.0024552.g004
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latest compensatory parC mutations could provide increase of both
resistance and fitness, suggesting that a higher level of resistance
could be selected in absence of antimicrobial exposure [29].
Our findings, obtained using an isogenic system in E. coli where
the qnr gene was cloned onto a simple replicative plasmid such as
pBR322, showed that qnr acquisition enhanced the bacterial fitness
in vitro and in vivo. Indeed when the only difference between two E.
coli strains was the presence of qnr with its flanking region, the
strain that acquired the qnr gene took over the susceptible strain in
absence of quinolone exposure. Several studies [13,14] suggested
that the low level quinolone resistance is relevant when the host is
exposed to quinolone in clinical situations. This could give a
partial explanation for widespread but not for emergence. Several
environment bacterial species, such as Shewanella algae or Vibrio
splendidus, have been shown to harbor chromosomal qnr-like genes
and are supposed to be the reservoir of qnrA3 and qnrS1,
respectively [15–18]. The enhancement of fitness we observed
after the acquisition by E. coli CFT073 of qnrA3 without
antimicrobial exposure could explain how qnr had first emerged.
This could have been the following scenario: the transfer from the
chromosome of S. algae to a mobile element replicating in E. coli,o r
another member of the Enterobacteriaceae family, due to qnr giving a
selective advantage. qnrD is the last qnr gene that was discovered in
2009 and it is carried onto a small non conjugative plasmid [58].
Although we did not test the fitness conferred by this small
replicative qnr-positive plasmid, similar to pBR322, we hypothe-
sized that the first step of the qnr emergence could have been
through mobilization onto small plasmids, which may have
resulted in an enhanced fitness as we showed in our in vivo
experiments. In addition, there might be low concentrations of
quinolones in the environment at some places which could have
contributed to the resilience of these bacteria harboring qnr genes
[59].
To investigate if their impact on fitness could also explain the
widespread of qnr genes, we measured the fitness after acquisition
of qnrA3 when included in a multidrug resistant plasmid as those
usually observed in clinical qnr-positive isolates [10,11,36,60].
When the gene was acquired with the whole multi drug resistant
plasmid pHe96, the host fitness was lessened. This could be
explained by the presence of another fitness impairing gene on the
plasmid. However, this fitness cost was not specific of pHe96 since
competitive experiments between E. coli CFT073 and two other E.
coli clinical strains with qnr containing MDR plasmids showed the
same fitness cost. Our experiments with an evolved clone of the E.
coli CFT073(pHe96) transconjugant suggest that the fitness cost
can be reduced by the host. Further explorations are needed to
investigate the mechanism of this compensation. The difference in
the impact on fitness when qnr is included into a large plasmid or
into a small non conjugative plasmid could also be a consequence
of a different level of qnr expression. However, MICs of quinolones
were the same in the two plasmids.
Whatsoever, this would mean that fitness gain could contribute
to the emergence of qnr-bearing plasmids among the bacterial
communities living in the environment (soil, water) and their
transfer to other bacteria such as those of the human commensal
flora [54]. For the widespread observed in the following years, the
fluoroquinolone resistance conferred and co selection with other
resistance determinant (particularly expanded-spectrum-beta-lac-
tamases, ESBL) would be the predominant selection factor
[61,62].
Native functions of Qnr proteins are still unknown. They bind
type II topoisomerases even without quinolone binding to their
targets [19,20]. Although known Qnr proteins usually do not
interfere with E. coli gyrase activity at the concentration they
prevent fluoroquinolone inhibition [10,19,21], Qnr-like proteins
inhibit catalytic activity of topoisomerases from their natural host
[21,63]. Crystallographic data on the structure of Qnr-like PRPs
such as MfpA [22], EfsQnr [23] and AhQnr [24], revealed a right
handed b helix structure that mimics a double-strain helix DNA.
This could permit interaction with other DNA-linked proteins
with a possible regulating function of the activity of these proteins.
Mimicking DNA structure could have consequences on cell cycle
and replication. Thus, this could explain the impact on fitness.
Limitations
Plasmid instability was significant for some of our plasmid
constructions, even the native plasmid pHe96. However our
analysis took into account this plasmid loss. Overall, artificial
plasmids constructed from pBR322 were less stable than plasmids
naturally isolated from clinical strains.
Materials and Methods
Ethics Statement
Animal experiments were performed in accordance with
prevailing regulations regarding the care and use of laboratory
animals by the European Commission. The experimental protocol
was approved by the Departmental Direction of Veterinary
Services in Paris, France (agreement Nu A 75-18-05, 2005). The
procedures are conformed to the Amsterdam protocol on animal
protection and welfare and Directive 86/609/EEC on the
protection of animals used for experimental and other scientific
purposes.
All manipulation of animals were be carried out by qualified
personnel. All protocols will be done in accordance with the local
institutional review board (Comite ´ d’Ethique en expe ´rimentation
animale, Ile de France, Paris Comite ´ 3).
Bacterial strains and plasmids
E. coli CFT073 strain is a clinical isolate susceptible to all
antibiotics [32], which was used previously to set the murine
model of pyelonephritis [13,33]. The plasmid pBR322 vector
(4,361 bp) carries a bla gene encoding ampicillin resistance and a
tetA gene encoding tetracycline resistance [64,65]. The plasmid
pHe96 was previously isolated in a Klebsiella pneumoniae cultivated
from feces in a patient with cancer. The strain was described
before [16] and the plasmid was sequenced for the 10 kb DNA
fragment flanking qnrA3 (GenBank accession number EU495237).
qnrA3 is a gene homologous to the chromosome-borne qnr allele
found in S. algae strains [18] and was only described as plasmid-
borne in the plasmid pHe96 [16].
E. coli J53 strain is a recipient strain widely used for conjugation
with plasmid carrying qnr alleles [6,36]. E. coli J53 transconjugants
were obtained after conjugation with the following clinical strains:
E. coli pHm477 (qnrA1) [11], K. pneumoniae pHe96 (qnrA3) [16], E.
coli pPS105 (qnrS1) [13], E. coli pHm13 (qnr A1) [13] and E. coli
pU1696 (qnrB4) [37]. These two latter strains, which were
uropathogenic clinical isolates harboring multi drug resistance
plasmids containing qnrA1 and qnrS1, respectively, were used for
competitive experiments against susceptible E. coli CFT073.
qnrA3 cloning into pBR322
Cloning of the qnrA3 gene and its flanking region was done
including either the 24 nucleotides (M24) upstream from qnrA3,
resulting in the plasmid pBRAM1, or the 233 nucleotides (M233)
upstream, resulting in the plasmid pBRAM2, and 29 nucleotides
downstream for both. These upstream regions M24 and M233 are
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supposed to contain the promoter region [36,66]. Amplification
was performed using a sense primer containing an EcoRV
restriction site (underlined) (59-ATACTTCCGATATCCCCCT-
CCCTGATT-39 for the fragment included in pBRAM1 and 59-
CTGACTGATATCCCCAAATCCAACACT-39 for the frag-
ment included in pBRAM2) and a SalI restriction site (underlined)
in the reverse primer (GCAAGCGTCGACTCAAGTGATATT-
TGC for both DNA amplified fragments). Plasmid DNA of K.
pneumoniae He96 was used as the template. PCR was performed in
a2 5ml mixture including 10 ml forward and reverse primers, 5 ml
DNA template and one Illustra
TM pure Taq
TM Ready-To-Go
TM
PCR bead (GE Healthcare, Buckinghamshire, UK). PCR was run
using the following program : 94uC for 4 min; 94uC for 1 min;
55uC for 1 min; 72uC for 1 min for 30 cycles; and 72uC for
10 min. The amplified fragment was purified using QiaquickH
PCR purification kit (QiagenH), digested with EcoRV and SalI
(Invitrogen
TM), and then ligated into the tetracycline resistance
tetA gene downstream of the promoter of pBR322 (Invitrogen
TM)
previously digested with EcoRV and SalI. The ligation product was
electroporated into competent E. coli CFT073. Transformants for
E. coli CFT073 with pBRAM1 or pBRAM2 were selected on
ampicillin (100 mg/ml)-containing Mueller-Hinton (MH) plates
and replicated on tetracycline (20 mg/ml)-containing plates to
identify inserts.
The control strains were E. coli CFT073(pBR322), where the
plasmid pBR322 was electroporated into competent E. coli
CFT073, and E. coli CFT073(pBRDtetA) where the tetA gene in
the vector pBR322 was inactivated as follows: pBR322 was
digested with EcoRV and NruI, ligated without any insert, and the
product was electroporated in competent E. coli CFT073.
Susceptibility to tetracycline was tested to check tetA inactivation.
Figure S1 summarizes in a scheme the methods used to obtain the
pBR322 derivatives.
pHe96 containing strains and controls
A streptomycin-resistant mutant E. coli CFT073-Sm
R strain was
selected in vitro from E. coli CFT073 by plating 10
9 bacteria onto
MH agar containing streptomycin concentration from 10 to
160 mg/ml. The transconjugant E. coli CFT073-Sm
R(pHe96) was
obtained after conjugation between E. coli CFT073-Sm
R and K.
pneumoniae He96 [16] after 40 min of mating into MH broth as
previously described [13]. After incubation, transconjugants were
selected by plating the conjugation mixture on MH agar
supplemented with ampicillin (100 mg/ml) plus streptomycin
(100 mg/ml). PCR experiments (RAPD and PCR qnrA) were
performed as already described to confirm the success of the
conjugation [11,67].
E. coli CFT073-Sm
R(pHe96) ‘‘R42’’ is a clone of E. coli
CFT073-Sm
R(pHe96), which has been selected from kidneys of
an infected mouse. This clone was studied because it caused an
infection with a bacterial load in organs higher than with the other
clones of E. coli CFT073-Sm
R(pHe96).
Growth experiments and antibiotic susceptibility testing
Growth curves of each strain in TS broth were drawn using
automatic optical density measurements obtained by reader
infiniteH M200 (Tecan). After an overnight culture in TS broth
at 37uC, bacterial suspensions were diluted in order to reach an
Optical Density of 0.5, and then diluted 100 times. Microplates
were inoculated with the obtained suspensions. Each combination
of strain and medium was run in triplicate. The plates were
incubated at 37uC for 24 hours and subject to shaking during 60 s
every two minutes. Optical density (OD) at 600 nm was measured
every 5 minutes during this 24-hours period. The log10 of each
value of OD was calculated. To estimate the doubling time, a slope
was calculated between every two consecutive values. After
discarding artifacts, a mean of the six highest slopes was calculated,
corresponding to the maximal growth rate. Doubling time was
calculated as log10 2 divided by the maximal growth rate [57,68].
Maximal OD increase was also calculated as the mean of the ten
highest values of OD reached during stationary phase. This has
been performed five times for each strain.
The Minimal Inhibitory Concentrations (MICs) of nalidixic
acid, norfloxacin, ofloxacin and ciprofloxacin were determined for
each constructed strain and control strain by EtestH, according to
the instructions of the manufacturer. MICs of amikacin and
tobramycin were also measured in order to evaluate the expression
of aac(69)-Ib-cr. EtestH were performed on MH agar plates and the
plates were incubated 18 h at 37uC.
Plasmid stability
Since all the plasmids tested carried an ampicillin resistant
determinant, plasmid stability of the transconjugants E. coli
CFT073-Sm
R(pHe96), E. coli CFT073(pBRAM1), E. coli
CFT073(pBRAM2), E. coli CFT073(pBR322) and E. coli
CFT073(pBRDtetA) was measured in vitro by daily subculture
during ten days in antibiotic-free Trypticase Soy (TS) broth with
plating onto TS agar containing 100 mg/ml ampicillin and
antibiotic free TS agar plates. In vivo, at the end of each
experiment, organs were also spread onto ampicillin-containing
and antibiotic-free TS agar. Plasmid loss was calculated for each
organ as the ratio ampicillin resistant CFU/total number of CFU.
Flow cytometry
In order to check that OD variations were not caused by a
change of cell size, all the studied strains were also studied in flow
cytometry as already described [69]. Flow cytometric measure-
ments were performed on a Guava EasyCyte Plus flow cytometer
(Millipore, St Quentin en Yvelines, France) equipped with a
488 nm laser. Overnight cultures were diluted to a cell density of
ca. 10
5 CFU/ml. Cells were collected on the forward scatter with
logarithmic amplifiers for 5,000 events. The experiment was
replicated four times for each strain.
In vitro competitions experiments
Pairwise competition experiments were performed to evaluate
the in vitro relative fitness of each qnr-positive strain compared to
the qnr-negative control strain. We also performed competition
with the wild type strain E.coli CFT073. Each strain of its isogenic
system was incubated separately for 18 h at 37uC in TS broth.
The cell densities of the suspensions were estimated by flow
cytometry [70]. An aliquot containing 10
8 bacteria was taken from
each suspension and mixed two by two in a ratio of 1:1 to
inoculate 10 ml of TS broth and then incubated for 24 h at 37uC
for a competitive growth. The initial and the final densities of each
competitive strain were estimated from CFU data by diluting and
plating population samples onto TS agar with and without
antibiotic. Tetracycline was used to distinguish E. coli
CFT073(pBR322) from E. coli CFT073(pBRAM1) and E. coli
CFT073(pBRAM2) in the first isogenic system Ampicillin was used
to distinguish E. coli CFT073 from E. coli CFT073(pBRAM1) and
E. coli CFT073(pBRAM2). In the second isogenic system,
ampicillin was used to distinguish E. coli CFT073-Sm
R(pHe96)
from E. coli CFT073-Sm
R. With these densities, the Malthusian
parameter of each competitor could be calculated. The Relative
Fitness (RF) was calculated as the ratio of the two Malthusian
parameters [42–45] (RF=(logS1d12logS1d0)/log (S2d12logS2d0),
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respectively at the end and at the beginning of the competition
experiment, and S2d1 and S2d0 their equivalent values for the
control strain. A RF score .1 meant that the qnr+ strain had a
selective advantage upon the control strain whereas a score ,1
represented a fitness cost for qnr acquisition.
Mouse model of urinary tract infection
The ascending unobstructed mouse model of UTI was used as
previously described [13,33]. Animal experiments were performed
in accordance with prevailing regulations regarding the care and
use of laboratory animals by the European Commission. The
experimental protocol was approved by the Departmental
Direction of Veterinary Services in Paris, France. Eight-week-old
immunocompetent female CBA mice (weight, 20 to 23 g) were
used. Inocula of different strains were obtained by overnight
incubation in BHI broth, washing of the cells by centrifugation at
15,0006 g for 15 min, and resuspension in TS broth to a final
inoculum of 10
10 CFU/ml. Pyelonephritis was induced during
general anaesthesia (with an intraperitoneal administration of
Ketamin 150 mg/kg and Xylazin 0.5 mg/kg) by injecting 50 ml
(i.e., 5610
8 CFU) into the bladder through a urethral catheter.
In vivo growth experiments: single-strain infections
In order to evaluate their potentials to perform persistent UTI
and to reach a high bacterial density in bladder and kidneys, mice
were inoculated separately by each of the following strains: E. coli
CFT073-Sm
R, E. coli CFT073-Sm
R(pHe96) and E. coli CFT073-
Sm
R(pHe96) ‘‘R42’’. No antimicrobial was administrated. Mice
were sacrificed at two, five and ten days after inoculation with at
least 8 mice per group, and bladders and kidneys were aseptically
taken out, weighed and homogenized in 1 ml of saline solution.
Bacterial densities were estimated from CFU data by diluting and
plating organs samples onto TS agar and were expressed as the
number of CFU/g of tissue. The growth rate of each strain was
estimated by the bacterial densities in bladder and kidneys and
could be compared to the control strain. Plasmid loss on days 5
and 10 was assessed for strains harboring plasmid pHe96 by
comparing the number of CFU growing onto MH plates
containing or not ampicillin (100 mg/ml).
In vivo fitness measurements: competitive infections
The in vivo selective value of the qnr-positive strain compared to
the control qnr-negative strain was determined by competitive
experiments between the two isogenic strains using the same
mouse model of UTI. Inocula were prepared the same way that
for single-strain infection experiments, except that before mixing
the two suspensions, bacterial density was measured by flow
cytometry. Proportions of each suspension were adjusted so that
inoculum contained the two strains in a 1:1 ratio and that cell
density was at least 10
10 bacteria/ml. Inoculum was spread on
antibiotic containing plate to count the initial ratio. At least 20
mice were inoculated for each competitive experiment, and were
sacrificed at five or ten days after inoculation. After removing and
homogenizing bladders and kidneys, they were spread onto TS
agar plates without antibiotics and containing the appropriate
antibiotic to select one of the two competitive strains among the
population. Tetracycline (20 mg/ml) was used to distinguish
between strains harboring pBR322 or pBRAM2, and ciproflox-
acin (0.05 mg/ml) to distinguish strains harboring pBRAM2 or
pBRDtetA. To count the number of pBRDtetA-bearing cells, we
subtracted the number of cells growing onto ciprofloxacin-
containing plates from the number of cells growing onto
ampicillin-containing plates. Ampicillin (100 mg/ml) was used to
distinguish E. coli CFT073-Sm
R from its transconjugants, E. coli
CFT073-Sm
R(pHe96) and E. coli CFT073-Sm
R(pHe96) R42. For
competitions between strains carrying pBR322 or its derivatives,
bladders and kidneys were also spread onto ampicillin-containing
plates, in order to evaluate plasmid loss. A competitive index was
calculated for each organ as the ratio of the number of qnr-positive
cells/number of qnr-negative cells, corrected by the initial ratio.
Organs where no CFU grew were excluded.
Statistical analysis
Results were expressed as mean and 95% confidence interval
for continuous variables. Continuous variables were compared by
nonparametric (Wilcoxon) tests. Discontinuous variables were
compared by Fisher’s exact test. A p value less than 0.05 was
considered significant. Analysis was performed using the online
free software Biostatgv (http://www.u707.jussieu.fr/biostatgv).
Supporting Information
Figure S1 Scheme of qnrA3 cloning from its native
plasmid pHe96 into pBR322 and resulting qnr-positive
(pBRAM1 and pBRAM2) and control plasmids
(pBRDtetA). M24 and M233 are the fragments of 24- and
233-bp upstream from qnrA3 and described in pHe96 [16].
Primers (see text for sequences) Fw2, Fw1 and R contain the
EcoRV and SalI restrictions sites and were used to amplify the
qnrA3 DNA fragments.
(TIF)
Figure S2 Reduced fitness observed for clinical isolates
of E. coli harboring qnr-positive multi drug resistance
plasmids in competitive infections with E. coli CFT073
without antimicrobial exposure. Each symbol represents
the ratio (number of CFU for the qnr-positive strain/number of
CFU for the qnr-negative isogenic strain) in organs (blue
diamond=kidneys, red circle=bladder), collected five to forty
days after inoculation of a 1:1 mix of the two strains. Part
A: competition experiments opposing E. coli CFT073 (qnr2)a n d
E. coli Hm13 (qnrA1+). Thirty mice were inoculated, 27 bladders
and 30 pairs of kidneys were efficiently infected. Fifty-three
competitions were lost by the qnr+ strain and 2 only were won
(p,0.0001). Part B: competition experiments opposing E. coli
CFT073 (qnr2)a n dE. coli PS105 (qnrS1+). Thirty-three mice
were inoculated, 33 bladders and 30 pairs of kidneys were
efficiently infected. Forty-one competitions were lost by the qnr+
strain, and 17 were won (p,0.0001).
(TIF)
Table S1 In vitro growth parameters of E. coli J53 and its
transconjugants with qnr-positive multidrug resistant plasmids.
(DOC)
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